Article

Alcon completes acquisition of Sirion drugs

Alcon Laboratories Inc. has received regulatory approval and finalized the acquisition of the rights in the United States for difluprednate ophthalmic emulsion 0.05% emulsion (Durezol) and the global rights, excluding Latin America, for cyclosporine (Zyclorin) from Sirion Therapeutics Inc. Alcon immediately assumed responsibility for all marketing, promotion, and sales of the difluprednate formulation.

Huenenberg, Switzerland

-Alcon Laboratories Inc. has received regulatory approval and finalized the acquisition of the rights in the United States for difluprednate ophthalmic emulsion 0.05% emulsion (Durezol) and the global rights, excluding Latin America, for cyclosporine (Zyclorin) from Sirion Therapeutics Inc. Alcon immediately assumed responsibility for all marketing, promotion, and sales of the difluprednate formulation.

The difluprednate formulation is a topical ophthalmic corticosteroid used to treat postoperative inflammation and pain associated with ocular surgery. It received FDA approval in 2008. The cyclosporine formulation, not approved by the FDA, is a topical ophthalmic immunomodulator and immunosuppressive agent under clinical investigation to treat dry eye and other ocular surface diseases.

“This acquisition reinforces our ability to drive growth in the near-term with the acquisition of [difluprednate] and add products to our long-term research pipeline with [cyclosporine],” said Stuart Raetzman, Alcon’s vice president of global marketing and area president for the United States. “[Difluprednate’s] unique capability to . . . treat both inflammation and pain [effectively and quickly] following ocular surgery makes it a great fit for Alcon’s . . . product portfolio.”

In related news, Alcon management, in a news release, said that it is continuing to evaluate options to acquire Sirion’s ganciclovir ophthalmic gel 0.15% formulation (Zirgan), an antiviral recently approved by the FDA for the treatment of acute herpetic keratitis (corneal ulcers).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.